Results 161 to 170 of about 2,825,424 (355)

Prevent or Treat? Evaluating a Delayed Treatment With Nintedanib After Murine Orthotopic Tracheal Transplantation. [PDF]

Transplant Direct
Mauer J, Graebner C, Kuckhahn A, Ramsperger-Gleixner M, Weyand M, Heim C.   +5 more
europepmc   +1 more source

ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma‐cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study

Molecular Oncology, EarlyView.
Circulating tumor cells (CTCs) and plasma cell‐free DNA (cfDNA) were analyzed to detect ESR1 mutations and methylation in patients with advanced breast cancer. CTC‐derived DNA showed higher sensitivity for mutation detection and revealed complementary genetic and epigenetic alterations, highlighting the added value of CTC analysis for understanding ...
Dimitra Stergiopoulou, Athina Markou, Eleonora Nicolo, Mara S Serafini, Qiang Zhang, Youbin Zhang, Lorenzo Gerratana, Andrew A. Davis, Huiping Liu, William J Gradishar, Carolina Reduzzi, Massimo Cristofanilli, Evi Lianidou   +12 more
wiley   +1 more source

Inflammaging and Senescence-Associated Secretory Phenotype (SASP) in Psoriasis - A Narrative Review of Potential Mechanisms and Anti-Inflammaging Strategies. [PDF]

Psoriasis (Auckl)
Filipek K, Nowowiejska-Purpurowicz J, Flisiak I.   +2 more
europepmc   +1 more source

Transforming growth factors produced by certain human tumor cells: polypeptides that interact with epidermal growth factor receptors.

Proceedings of the National Academy of Sciences of the United States of America, 1980
G. Todaro, C. Fryling, J. E. D. Larco
semanticscholar   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Analysis of the mechanisms of resistance to Epidermal growth factor receptor inhibitors and development of multiple targeted strategies

, 2008
Background. Primary and acquired resistance to selective Epidermal growth factor receptor (EGFR) inhibitors remains the most significant obstacle to the success of these targeted agents in cancer therapy.
Rosa, Roberta
core  

Neurotransmitter-Mediated Signaling in Glioblastoma and Glial Tumors: Biology and Therapeutic Opportunities. [PDF]

Oncol Res
Tralongo P, Ballato M, Zuccalà V, Fiorentino V, Giordano W, Casili G, Bellinghieri F, Caruso G, Angileri FF, Fadda G, Martini M, Caffo M.   +11 more
europepmc   +1 more source

Epidermal growth factor receptors

Journal of British Surgery, 1985
A P Savage, T Cooke, R Sainsbury, J Farndon, A Harris   +4 more
openaire   +2 more sources

Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody.

Proceedings of the National Academy of Sciences of the United States of America, 1983
T. Kawamoto, J. Sato, L. Anh, J. Polikoff, G. Sato, J. Mendelsohn   +5 more
semanticscholar   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source